To include your compound in the COVID-19 Resource Center, submit it here.

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies.

ORIC Pharmaceuticals Inc. (South San Francisco, Calif.), which has now raised more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and

Read the full 561 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers